heute gaaanz billig geworden..... - 500 Beiträge pro Seite

[Piddy]

UTHR-united therapeutics
ca-54%
downgrade
gruss,piddy

[gholzbauer]

UTHR down 50.7%
Deutsche Banc Alex Brown downgraded from strong buy to MARKET PERFORMER
They see 2 year delay to profitability

[gholzbauer]

Jetzt 17 5/8$, -30$,
Mkp. 350 Mio. $, Cash 240 Mio. $, fast keine Schulden;

[Piddy]

hey
schon bei -63%.ist ja voll krass.ein kuebel vodka fuer den
der welche hat,ohne sl.
gruss,piddy

[puhvogel]

Ich bin auch schoan drin.
Ich besitze mittlerweile lauter Biotechs mit großen Cash-Beständen.
Heute auch endlich CNCT gekauft. Wie im 99-Pfennig-Laden hier....
Der COO hat aber auch seinen Rücktritt erklärt. Egal wenn die auch nur annähernd den geplanten Umatz für 2002 erreichen.....
Aber was Downgrades heute zu bedeuten haben...

[gholzbauer]

Ich kann mich nicht entschließen, ob ich hier einsteigen soll oder nicht. Mal weiter beobachten ...

[gholzbauer]

EquityAlert.com Announces Investment Opinion, No. 5
VANCOUVER, B.C., Dec 4, 2000 (BUSINESS WIRE) --

(OTCBB: EINC chart, msgs)

United Therapeutics Loses 59.32% On News Of Revenue Targets


EquityAlert.com, Inc. (www.EquityAlert.com), one of the largest re-distributors of public company and mutual fund news alerts, today forwarded free real time news alerts on a wide range of NASDAQ stocks.

Among the active issues available to our real time news alert subscribers so far today, Monday, December 4th, were United Therapeutics Corp. (NASDAQ: UTHR chart, msgs) and QUALCOMM Inc. (NASDAQ: QCOM chart, msgs).

United Therapeutics Corp. had lost 59.32% at 9:55 AM EST today, after announcing that, pending FDA approval of its UT-15 drug by mid-2001, it is targeting revenues for 2001 of approximately $10 to $20 million, and a 2002 revenue target of between $75 and $100 million.

[Piddy]

hey
hab mal einige daten zusammengetragen
52 wks high 128,5$ momentan ca.18$
73,47 institutions/insiders
12/99 -2,51
12/00 -1,78
12/01 0,39
csh
30.09.99 59,64 mill.$
30.09.00 238.53 mill.$!!!
gruss,piddy

[gholzbauer]

Die EPS-Schätzungen werden sicher demnächst nach unten angepaßt. Allerdings sollte das im jetzigen Kurs locker enthalten sein.

[puhvogel]

UTHR projections disappoint
--10:13 am - By Michael Baron
United Therapeutics (UTHR: news, msgs) is plunging $28.25, or 59.3
percent, to $19.38, after the Silver Springs, Md., biotechnology firm said it
expects revenue of $10 million to $20 million in fiscal 2001 from UT-15,
or Uniprost, its subcutaneous treatment for pulmonary arterial
hypertension. Deutsche Banc Alex Brown cut its rating on UTHR to
"market perform," saying this projection is significantly below its
expectations for revenue of $80 million. United Therapeutics said the
FDA has indicated its cardiovascular and renal drugs advisory
committee will review the company`s new drug application for UT-15 on
February 9. The company said it expects revenue of $75 million to $100
million from Uniprost in 2002. Deutsche Banc was looking for revenue of
$170 million in the same period. In addition, United Therapeutics
co-founder James Crow will retire as president and chief operating
officer when the company obtains FDA approval for UT-15. Crow will be
replaced by Roger Jeffs, vice president for clinical, scientific & medical
affairs. Other negative developments, according to Deutsche Banc,
include the slow enrollment in UTHR`s open-label study of UT-15, and
the company`s decision to seek approvals on a country by country basis
in Europe. The firm had been anticipating a Europe-wide filing in the
fourth quarter.
---------------
Was lernen wir daraus: Analysten haben wohl nicht den geringsten Schimmer, wieviel ein Medikament in Zukunft verdienen wird.

[gholzbauer]

Prudential Sec., 5.12.00
United Therapeutics

UTHR: LOWERING ESTIMATES BASED ON REVISED OUTLOOK; MAINTAIN HOLD


UTHR | $17.94 | NASD HOLD


We have reduced our 2001-2003 Uniprost sales and EPS estimates and adjusted our profitability timeline from 2001 to 2003 based on a revised outlook for the future marketability of Uniprost.


Based on our conversations with leading pulmonologists combined with the huge need for newer PH treatments, we believe the FDA approval of Uniprost by mid-2001 is likely, despite its controversial clinical profile.


However, the potential that the labeling for Uniprost will be limited to just the primary pulmonary hypertension (PH) patients still remains and represents a significant risk factor to our revised estimates.

[gholzbauer]

Tuesday December 5, 7:55 pm Eastern Time
Press Release
SOURCE: United Therapeutics Corporation
United Therapeutics Announces Stock Repurchase Program
SILVER SPRING, Md., Dec. 5 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that its Board of Directors approved a stock repurchase program of up to 3,000,000 shares of its outstanding stock over the next six months.

It is anticipated that these purchases will be made at management`s discretion in the open market and/or through privately negotiated transactions, subject to market conditions. United Therapeutics further announced that some members of its Board of Directors and senior management also plan to make market purchases of the company`s stock. There are approximately 20,185,000 shares of United Therapeutics common stock outstanding.

``Our board of directors and management believe that United Therapeutics` stock is substantially undervalued by the market and we decided to take advantage of this opportunity to capture some of this value for our continuing shareholders,`` said Martine Rothblatt, Chairman and CEO of United Therapeutics. ``With approximately $230 million in cash, cash equivalents and investments, our financial position is sufficiently strong to allow for both this stock repurchase and our continued drug development program. The board`s decision to initiate a stock repurchase program underscores our belief that United Therapeutics` shares are substantially undervalued and demonstrates our commitment to enhance shareholder value.``

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products.

SOURCE: United Therapeutics Corporation

[gholzbauer]

Monday December 4, 1:56 pm Eastern Time
Morningstar.com
Stay Away from United Therapeutics
By Emily Hall


What Happened?
The market destroyed United Therapeutics (Nasdaq: UTHR - news) on Monday, sending the stock down about 63% in intraday trading. The sell-off was driven by Friday`s innocuously titled press release: ``United Therapeutics Plans Expected Transition to Commercial Operations.`` In the announcement, however, the company indicated that sales of its flagship Uniprost, which is expected to be approved by the Food and Drug Administration early in 2001, would probably total $10-$20 million in the product`s first year on the market--much lower than earlier estimates. The release also said United`s chief operating officer, James Crow, and its executive vice president for business development, Gilles Cloutier, would both be leaving early next year.

What it Means for Investors
Although we love bargains in the biotech sector, we believe that United Therapeutics has too many lingering questions to make it a compelling pick right now.

The double whammy of downward revenue projections and the loss of two executives makes United Therapeutics unappealing. The company is facing some serious potential competitors in the pulmonary hypertension market, such as Swiss biotech firm Actelion. On the bright side, United does have two other products, Beraprost and Ketotop, in late-stage human trials, but at this point it`s not clear that these products can offset the lost revenue from a potentially slow-growing Uniprost. Thus, we believe investors are better off looking elsewhere at present.

Emily Hall can be reached at [e-mail].

Get Morningstar`s unbiased analyses of 750 stocks and 2000 funds, free for 30 days.

[puhvogel]

Das wichtige dabei ist, dass schon vorher die Aktie stark gefallen ist. Es haben sich wohl schon vorher einige verabschiedet.
Einen schnellen Aufstieg erwarte ich aber jetzt auch nicht mehr.
Solange VPHM mit einer Bewertung am Bargeldbestand, neuen Ergebnissen in drei-vier Monaten und einem Hep C Produkt in Phase 2 nicht steigen will, wird der Markt für fallen angels schwierig bleiben. Gestern haben meine Werte extrem underperformt.
Solange aber eine Cisco so "billig" ist, wird eine UTHR es schwierig haben. SUPG zeigt aber, das beim Turnaround nicht lange gewartet wird (die News waren mehr der psychologische Auslöser als der Anlaß).
Weiß jemand, wann die Ergebnisse der anderen Trials anstehen?
Der Puhvogel

[puhvogel]

Hmmm. Die wollen 3 Millionen ihrer Aktien zurückkaufen.
Wenn sie geschickt sind, und ein wenig abwarten, udn die Rückkaufe mit eine paar netten news garnieren, könnten die den shorts das Leben schwer machen.
Oftmals bringt das aber auch nichts, manchmal aber schon (SUPG)

United Therapeutics Announces Stock Repurchase Program

SILVER SPRING, Md., Dec. 5 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that its Board of Directors
approved a stock repurchase program of up to 3,000,000 shares of its outstanding stock over the next six months.
It is anticipated that these purchases will be made at management`s discretion in the open market and/or through privately negotiated transactions, subject to market
conditions. United Therapeutics further announced that some members of its Board of Directors and senior management also plan to make market purchases of the
company`s stock. There are approximately 20,185,000 shares of United Therapeutics common stock outstanding.
``Our board of directors and management believe that United Therapeutics` stock is substantially undervalued by the market and we decided to take advantage of
this opportunity to capture some of this value for our continuing shareholders,`` said Martine Rothblatt, Chairman and CEO of United Therapeutics. ``With
approximately $230 million in cash, cash equivalents and investments, our financial position is sufficiently strong to allow for both this stock repurchase and our
continued drug development program. The board`s decision to initiate a stock repurchase program underscores our belief that United Therapeutics` shares are
substantially undervalued and demonstrates our commitment to enhance shareholder value.``

[gholzbauer]

Thursday December 7, 10:44 pm Eastern Time
Press Release
SOURCE: United Therapeutics
United Therapeutics Discontinues Ketotop Osteoarthritis Program Based On Phase 3 Trial Results
SILVER SPRING, Md., Dec. 7 /PRNewswire/ -- United Therapeutics (NASDAQ: UTHR - news) announced today that it has received the results from its Phase 3 study investigating the transdermal patch Ketotop for the treatment of osteoarthritis of the knee.

While individual endpoints in the 500 patient study achieved statistical significance, the key clinical and regulatory endpoint related to pain reduction did not meet the company`s expectations. Based on these results, United Therapeutics has decided to discontinue development of Ketotop which the Company had expected to launch in 2003 had the data been favorable.

``While we`re disappointed with the results of this study, Ketotop has never been a primary target product for us,`` said Martine Rothblatt, Chairman and CEO of United Therapeutics. ``We remain committed to achieving approval and commercializing our lead drugs, UT-15 and Beraprost, as well as to further developing our next generation prostacyclin molecules and our broad iminosugar platform. Our pipeline remains robust, with our pulmonary hypertension product pending FDA approval, our intermittent claudication product halfway through its second Phase 3 trial, our critical limb ischemia product in Phase 2 and our hepatitis B product nearing Phase 1. In addition, we are reviewing a number of acquisition opportunities.``

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products.

SOURCE: United Therapeutics

[puhvogel]

Wollte ich gerade auch reinstellen, nachdem ich meine 100 Stück verkauft habe.
Andersherum hätte es einen netten squeeze gegeben.
Na ja Anlegerrisisko.

[gholzbauer]

Warst Du dann das in Stuttgart?
Offenbar könnte man noch weitere Stücke in St und Be verkaufen, Geldkurse waren vorhin noch vorhanden.
Bin schon gespannt auf die Nasdaq-Kurse. Ich habe die Nachricht mit Zeitangabe 7.Dez. 10:44 pm gefunden, d.h. nachbörslich konnte man darauf evtl. noch gar nicht reagieren.
Gut, daß ich mich nicht entscheiden konnte einzukaufen.

[puhvogel]

Jo freilich.
Die Makler an den kleinen Börsen wie Stuttgart, München, Berlin bieten in der Regel einen Bid/Ask-Kurs an. Solange kein Verkaufsdruck über Instinet und Co. oder über den Parketthandel aufkommt, bleibt der Kurs stabil.
Bei kleinen Volumina und illiquiden Handel kaufeverkaufe ich gerne direkt über den MarketMaker, bevor meine Order von 300 Euro -Orders zerhackstückselt wird und der Frankfurter Makler wieder mal 1. Sieger beim Courtage einfahren ist.
Vielen Dank noch mal für die CVTX-Info!
@AXO.TO: Dompe könnte schwerlich zum aktuellen Marktpreis 3,5 Millionen Aktien über den freien Markt erwerben, wollen sie sicher auch nicht. Vor einem Monat waren die Aktien noch doppelt so teuer.
Grüße!
Der Puhvogel

[gholzbauer]

Bis jetzt scheibar kein größerer Verkaufsdruck.
Island liefert 2000 St. Umsatz zu 14,81$.
Ich dachte, UTHR geht sofort auf 10$.

[gholzbauer]

Ich fasse es nicht. Nach so einer Meldung im Plus.
Ketotop wurde wohl nur sehr wenig Wert zugemessen.
Allerdings hätte ich zumindest den Sentiment-Schaden für größer gehalten.
Es kommt eben immer anders ...

[puhvogel]

Jaa, ich schau aktuell auch ziemlich dumm aus der Wäsche.
Heute morgen hatte ich einen Moment gezögert, weil vorher schon eine desillusionierende, schlechte Nachricht herauskam.
Wie diesen Sommer bei Zona, die auch beim Cash-Wert notierten, mochten sich neue schlechte Nachrichten nicht mehr richtig negativ auf den Kurs auswirken.
Aber dann dachte ich an das aktuelle Tax-selling und dachte mir, man muss nicht alles abwarten.
Der Markt ist nicht sooo klein. Immerhin hat UTHR eine 500 Patienten Studie gesponsert, insgesamt kosten alle aktuellen Studien zusammen wohl 4 Mio $ im Quartal.
Aber was solls.. Lamentieren bringt nichts: Der Kursanstieg auf eine schlechte Nachricht, ist eigentlich ein bullishes Zeichen, aber wahrscheinlich steckt auch das Rückkaufprogramm dahinter.
SchöWE

[puhvogel]

Vielleicht passt dieser Kommentar, obwohl zu einer anderen Aktie gehört:
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=7076553&…
Er klingt oft irgendwie unglaubwürdig, aber Tundratyke hat den Markt 2 mal so haargenau vorhergesagt, dass mir der Mund offenstand.
Vorgestern hatte er zB das NDA-filing für die beiden daraufolgenden Tage vorhergesagt.

[gholzbauer]

Friday December 15, 8:51 am Eastern Time
Press Release
SOURCE: United Therapeutics Corporation
United Therapeutics Announces UT-15 NDA Will Not Require FDA Advisory Committee
RESEARCH TRIANGLE PARK, N.C., Dec. 14 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that it has agreed with the FDA that United Therapeutics` New Drug Application (NDA) for UT-15 (with the pending name of Uniprost) does not need to be presented to the Cardiovascular and Renal Drugs Advisory Committee. United Therapeutics submitted its UT-15 NDA on October 16, 2000 and was granted six-month priority review on October 19, 2000. United Therapeutics had previously been advised by the FDA that the Advisory Committee review would occur on February 9, 2001. UT-15, being developed by United Therapeutics as a subcutaneous treatment for pulmonary arterial hypertension, is an analog of prostacyclin, a molecule produced naturally within the body to keep blood vessels healthy.

This decision allows United Therapeutics to continue its close working relationship with the FDA toward approval of the UT-15 NDA in the six-month priority review timeline.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products.

SOURCE: United Therapeutics Corporation

[gholzbauer]

Kann mir jemand verraten, wie man "betrifft Aktie" einfügen/ändern kann? Bei mir funktioniert es überhaupt nicht mehr.

[gholzbauer]

Sunday December 17, 11:43 pm Eastern Time
United Therapeutics adopts shareholder rights plan
SILVER SPRING, Md., Dec 17 (Reuters) - Biotechnology company United Therapeutics Corp (NasdaqNM:UTHR - news) on Sunday said its board approved a shareholder rights plan designed to discourage unwanted takeover attempts.

The Silver Spring, Md.-based company has seen its stock value fall 88 percent from its high in June.

``We are particularly concerned that the future benefits of current programs and initiatives could be denied to stockholders by an opportunistic, undervalued acquisition of the company,`` Martine Rothblatt, United Therapeutics` chairman and chief executive, said in a statement.

The plan is triggered if a person or group acquires 15 percent or more of United Therapeutics` common stock or announces a tender offer which would result in such ownership, the company said.

Specifically, the plan provides for a dividend distribution of one right for each outstanding share of United Therapeutics common stock.

The dividend distribution will be made to stockholders of record on Dec 29, the company said.

United Therapeutics` shares finished at $15-11/16 on the Nasdaq Friday. The stock has a 52-week high of $132 and a 52-week low of 14-3/8.

-- New York Newsroom [phone]

[gholzbauer]

Monday December 18, 7:01 am Eastern Time
Press Release
SOURCE: United Therapeutics Corporation
United Therapeutics Acquiring Cooke Pharma, Expanding into Angina and Coronary Artery Disease
SILVER SPRING, Md. and BELMONT, Calif., Dec. 18 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that its wholly owned subsidiary, Unither Pharmaceuticals, Inc., is acquiring all of the assets of Cooke Pharma, Inc., the exclusive maker of the HeartBar®, the first and only medical food for angina and other cardiovascular conditions. Medical foods are regulated by the FDA.

The HeartBar relieves the symptoms of heart disease by increasing the diameter of blood vessels and thereby increasing blood flow. Clinical studies conducted by Cooke Pharma have demonstrated convincingly the ability of the HeartBar to reduce painful symptoms of cardiovascular disease, increase exercise tolerance and improve the quality of life. Privately held Cooke Pharma is the only company that owns the patent rights to use the HeartBar`s key ingredient, arginine, in a food product for cardiovascular diseases. Cooke Pharma sold over four million HeartBars as an over-the-counter product during 1999-2000.

The HeartBar, which is included in the Physicians Desk Reference, increases the relaxing effect of nitric oxide produced by blood vessels. In 1998, three American scientists received the Nobel Prize for their discovery that healthy blood vessels make nitric oxide, which keeps them relaxed and open. Randomized, double-blinded clinical studies published in leading medical journals and presented at the 2000 American Heart Association conference have shown that the HeartBar reduces angina and significantly improves exercise ability as compared to placebo. Cooke Pharma has other products in development based on its issued and pending patents targeting those at risk of heart disease and for overall cardiovascular health.

The Cooke Pharma Scientific Advisory Board includes two Nobel Laureates in Medicine, Sir John Vane and Dr. Louis Ignarro, as well as the Chairman of Medicine of Harvard Medical School, Dr. Victor J. Dzau, among other experts in cardiology. The founder of Cooke Pharma, Dr. John Cooke, is the Director of Vascular Medicine at the Falk Center for Cardiovascular Research at Stanford University.

``With the acquisition of Cooke Pharma`s impressive technology platform, United Therapeutics gains a pioneering medical food product with dynamic growth potential in the $13 billion heart disease market, as well as the larger market of 60 million Americans who are at risk of developing heart disease,`` said Dr. Barry Kanarek, President and COO of Unither Pharmaceuticals. ``Cooke Pharma complements United Therapeutics` mission to develop highly effective, clinically proven therapies to combat cardiovascular disease,`` Dr. Kanarek said.

The acquisition is structured as a taxable stock-for-assets purchase with a residual royalty stream. United Therapeutics will issue approximately 300,000 shares of its common stock to Cooke Pharma, subject to adjustment within a year, and Unither Pharmaceuticals agreed to pay a single-digit cash royalty to Cooke Pharma on sales of Cooke Pharma products up to an additional $49 million, subject to possible reduction. Unither Pharmaceuticals will create a new wholly owned subsidiary which will operate under the Cooke Pharma name and will be managed by Cooke Pharma`s existing management team. Closing of the asset purchase agreement is contingent upon several consents and approvals, including approval of the transaction by Cooke Pharma`s shareholders by December 31, 2000.

``This transaction will create a winning combination that can benefit millions of consumers and patients who have or are at risk of developing heart and vessel disease,`` said John Cooke. ``Both United Therapeutics and Cooke Pharma share a strong commitment to improving cardiovascular health and saving lives. We believe United Therapeutics has the vision, clinical expertise and resources to make the HeartBar and future formulations market leaders worldwide,`` continued Dr. Cooke.

Dr. Kanarek added, ``Led by Dr. Cooke, Cooke Pharma has a respected record of combining medical science with product innovation. We expect the HeartBar could become an important weapon against heart disease.``

Through his own extensive research at Stanford University, Dr. Cooke pioneered the use of arginine and other nutrients to improve vessel function and relieve symptoms in patients with peripheral vascular disease and with coronary artery disease. Dr. Cooke formulated these nutrients into medical foods and founded Cooke Pharma in 1995 to produce and market the products. The HeartBar is available over-the-counter at pharmacies nationwide. Cooke Pharma has plans to launch a second product, a drink, in 2001.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products.

SOURCE: United Therapeutics Corporation

[gholzbauer]

[puhvogel]

United Therapeutics Corporation Completes Enrollment In Phase III Intermittent Claudication ("Schaufensterkrankheit")Study

RESEARCH TRIANGLE PARK, N.C., Feb. 20 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR - news) announced today that it has completed enrollment in its Phase III study of oral beraprost in patients with intermittent claudication. Approximately 700 patients were randomized into the double-blind placebo- controlled study, one of the largest studies ever conducted in patients with intermittent claudication (pain when walking) due to peripheral vascular disease. Fifty-nine centers in the United States have enrolled patients in the study, which began enrollment in January 2000.
Peripheral vascular disease is caused by arteriosclerosis (hardening of the arteries) and affects six to eight million Americans, particularly those over 60 years of age. These patients suffer from a reduced quality of life and have an increased risk of heart attack and stroke. Intermittent claudication is a debilitating consequence of peripheral vascular disease that occurs when blood flow to the lower limbs is not sufficient to supply the demands of muscle tissue during walking. Efficacy results from the study are expected to be available late 2001. The study is assessing the effects of beraprost on exercise treadmill test walking distance after 24 weeks of treatment.
``The study is progressing well,`` said F. Jo Baker, RN, Manager of Clinical Affairs for United Therapeutics. ``We are grateful to our outstanding team of investigators for rapid recruitment of these patients.``
Beraprost was well tolerated and improved treadmill walking distance to a highly significant degree in the first Phase III study of beraprost in 422 patients with intermittent claudication, conducted by Hoechst Marion Roussel (now Aventis) in France and Italy. Results from the first trial, BERCI2, were published in the journal Circulation in July 2000. Data from both BERCI2 and the U.S. trial will be part of United Therapeutics` U.S. New Drug Application for beraprost in intermittent claudication, pending the results of United Therapeutics` ongoing U.S. trial.
``Our trial was designed to confirm the very positive results of BERCI2,`` said Michael Wade, Ph.D., Associate Director of Research and Development for United Therapeutics. ``Successful completion of this study will be an important milestone in our goal of filling a large unmet medical need for safe, effective treatments for intermittent claudication, which affects millions of people.``
Beraprost is the first and only orally available analog of prostacyclin, a potent naturally occurring vasodilator and inhibitor of platelet aggregation. Beraprost was exclusively licensed to United Therapeutics by Toray Industries, Inc. of Japan for the North American market. In Japan, beraprost has been proven in clinical studies to be safe and effective for the treatment of peripheral vascular disease. The drug has been approved in Japan since 1994 and Toray`s annual sales of beraprost there exceed $250 million.
A Japanese study presented at the 1998 American Heart Association meeting suggests that beraprost may also improve survival in patients with pulmonary hypertension. United Therapeutics is conducting a Phase III clinical trial program for beraprost to treat pulmonary arterial hypertension.

Ja, ja Biotech ist teuer, und der Euro erst ...

[puhvogel]

Hieran sieht man aml wieder, dass man die alten Nachrichten aufbewahrt. Die Hälfte der postiven Nachrichten vergisst man wieder....
Die Überschrift gilt meiner Meinung nach immer noch und UTHR ist zumindestens ein short term buy (ohne Gewähr):
United Therapeutics` Remodulin hearing set for August

SILVER SPRING, Md., June 26 (Reuters) - Biotechnology company United Therapeutics Corp. (NasdaqNM:UTHR - news) said on Tuesday it will present a benefit-to-risk profile for its pulmonary hypertension drug, Remodulin, before a Food and Drug Administration (FDA) committee on Aug. 9 or 10.
In April, United Therapeutics said the FDA had delayed approval on Remodulin`s new drug application, pending new data to support the filing. The application on Remodulin was originally filed in October 2000.
United Therapeutics will present the data before the FDA`s Cardiovascular and Renal Drugs Advisory Committee.